Revised Regulations on Nicotine and Non-Nicotine Vaping Products

Sep.30.2024
Revised Regulations on Nicotine and Non-Nicotine Vaping Products
DTI revises regulations on e-cigarettes and non-nicotine products, setting max nicotine content and online sales guidelines.

On September 30th, the Department of Trade and Industry (DTI) of the Philippines announced on its official website the implementation guidelines for Republic Act 11900 (RA11900), also known as the "Vaporized Nicotine and Non-Nicotine Products Regulation Act." The document specifies that the maximum nicotine content in vapor products should not exceed 65mg/ml, and the DTI, along with the Food and Drug Administration (FDA), will collaborate on setting technical standards for vaporized nicotine and non-nicotine products.


The revised content is as follows:


Product standards:


According to Section 18 of RA11900, the Office for Special Tasks on Vaping Products containing Nicotine and Non-Nicotine (OSMV) will work together with the Philippines FDA to formulate and release technical standards for products to ensure their compliance and safety. Vaping products with a nicotine content exceeding 65mg/ml are not allowed to be sold in the market. Compliance with these product standards is mandatory.


Product registration:


According to Article 19 of RA11900, all vapor products and novel tobacco products must be sold online through sellers or distributors registered with the DTI or Securities and Exchange Commission (SEC) to be sold through the internet or ecommerce platforms. Products sold and advertised online must comply with health warning requirements and other requirements of the Bureau of Internal Revenue (BIR), including tax stamps, minimum or floor prices, or other fiscal markings.


Online sales:


E-commerce platforms and social media sales facilities are only allowed to sell vaporized nicotine and non-nicotine products, their equipment, and novel tobacco products by distributors or retailers registered with the DTI and BIR.


Restrictions on sales and promotions around the school.


It is prohibited to sell, promote, advertise, or display vaporized nicotine and non-nicotine products or new tobacco products within 100 meters of schools.


Designated Smoking Area (DVA) standards:


The standard for the installation of a DVA has been established, requiring individuals or entities looking to install indoor DVAs in buildings and/or locations to first obtain approval from the OSMV.


Illegal products recalled, banned, or confiscated: OSMV can order the recall, prohibit, or seize from public sale or distribution any mist nicotine and non-nicotine products, their equipment, or new tobacco products that do not comply with RA11900, IRR, technical regulations, or their amendment provisions.


Establishment of the Special Task Office:


In order to specifically manage and oversee the taxation of vapor products, DTI has established the "Special Task Office for Vaporized Nicotine and Non-Nicotine Products (OSMV)". This agency will ensure that all vapor products on the market meet technical standards and are effectively taxed.


Online Brand List:


OSMV and BIR will maintain a monthly updated online list, listing brands of atomized nicotine or non-nicotine products, their devices, or new tobacco products eligible for online sale registered by DTI and BIR.


The revision aims to further strengthen the regulation of atomized products, heated tobacco products (HTP), and their equipment, ensuring that these products produced, sold, and distributed in the Philippines market meet international standards, safeguarding public health and safety, and ensuring that the government effectively collects relevant taxes.


The order will take immediate effect after being published in at least two widely circulated newspapers.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
China’s Shanghai Tobacco Group Launches CNY 10.98 Million (Approximately US$1.53 Million) Procurement for Heated Tobacco Production Utility Equipment
China’s Shanghai Tobacco Group Launches CNY 10.98 Million (Approximately US$1.53 Million) Procurement for Heated Tobacco Production Utility Equipment
Shanghai Tobacco Group Co., Ltd., a tobacco manufacturing company under China National Tobacco Corporation (CNTC), has launched a public tender for heated tobacco products (HTPs) production utility equipment at its Shanghai Cigarette Factory. The project is valued at CNY 10.98 million and covers six combined air-conditioning units, electrical cabinets and control systems for production facilities. The procurement includes equipment design, supply, installation, commissioning and related training services.
Aug.07
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
The Zhengzhou Tobacco Research Institute of China National Tobacco Corporation has filed a patent application for an end-to-end method to analyze the migration and transformation of chemical compounds in heated tobacco products. Using GC-Orbitrap/MS non-targeted analysis, the method compares tobacco substrate and aerosol samples to distinguish compounds transferred directly from the substrate from those newly formed during heating, while also calculating transfer rates. In an example involving nine heated tobacco products, the patent identified 17 newly formed thermal decomposition compounds and 38 transferred compounds.
Aug.13
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11